Dronabinol - Generic Drug Details

What are the generic sources for dronabinol and what is the scope of freedom to operate?

Dronabinol is the generic ingredient in three branded drugs marketed by Ascent Pharms Inc, Hikma, Insys Therap, Lannett Co Inc, Svc Pharma, Alkem Labs Ltd, and Wellhouse Pharma, and is included in seven NDAs. There are four patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Dronabinol has four patent family members in four countries.

There are eleven drug master file entries for dronabinol. Ten suppliers are listed for this compound.

Summary for dronabinol

International Patents:	4
US Patents:	4
Tradenames:	3
Applicants:	7
NDAs:	7
Drug Master File Entries:	11
Finished Product Suppliers / Packagers:	10
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	115
Patent Applications:	7,785
Drug Prices:	Drug price trends for dronabinol
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for dronabinol
What excipients (inactive ingredients) are in dronabinol?	dronabinol excipients list
DailyMed Link:	dronabinol at DailyMed

See drug prices for dronabinol

Recent Clinical Trials for dronabinol

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute on Drug Abuse (NIDA)	PHASE3
National Institute on Drug Abuse (NIDA)	PHASE2
Baylor College of Medicine	PHASE2

See all dronabinol clinical trials

Pharmacology for dronabinol

Drug Class

Cannabinoid

Medical Subject Heading (MeSH) Categories for dronabinol

Analgesics, Non-Narcotic

Cannabinoid Receptor Agonists

Hallucinogens

Psychotropic Drugs

Anatomical Therapeutic Chemical (ATC) Classes for dronabinol

A04AD	Other antiemetics
A04A	ANTIEMETICS AND ANTINAUSEANTS
A04	ANTIEMETICS AND ANTINAUSEANTS
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for DRONABINOL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SYNDROS	Oral Solution	dronabinol	5 mg/mL	205525	1	2017-04-17

US Patents and Regulatory Information for dronabinol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wellhouse Pharma	SYNDROS	dronabinol	SOLUTION;ORAL	205525-001	Mar 23, 2017		DISCN	Yes	No	11,253,472		Y	Y
Alkem Labs Ltd	MARINOL	dronabinol	CAPSULE;ORAL	018651-002	May 31, 1985	AB	RX	Yes	Yes
Insys Therap	DRONABINOL	dronabinol	CAPSULE;ORAL	078501-002	Aug 19, 2011		DISCN	No	No
Ascent Pharms Inc	DRONABINOL	dronabinol	CAPSULE;ORAL	207421-001	Feb 7, 2020	AB	RX	No	No
Svc Pharma	DRONABINOL	dronabinol	CAPSULE;ORAL	078292-001	Jun 27, 2008		DISCN	No	No
Insys Therap	DRONABINOL	dronabinol	CAPSULE;ORAL	078501-003	Aug 19, 2011		DISCN	No	No

Expired US Patents for dronabinol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alkem Labs Ltd	MARINOL	dronabinol	CAPSULE;ORAL	018651-001	May 31, 1985	6,703,418
Alkem Labs Ltd	MARINOL	dronabinol	CAPSULE;ORAL	018651-002	May 31, 1985	6,703,418
Alkem Labs Ltd	MARINOL	dronabinol	CAPSULE;ORAL	018651-003	May 31, 1985	6,703,418

International Patents for dronabinol

Country	Patent Number	Title	Estimated Expiration
Canada	2698752
World Intellectual Property Organization (WIPO)	2009020666
European Patent Office	2184983
Japan	2010535774

Market Dynamics and Financial Trajectory for Dronabinol

Last updated: March 2, 2026

What is the current market landscape for Dronabinol?

Dronabinol, a synthetic THC analog, has been approved by the U.S. Food and Drug Administration (FDA) since 1985 for two primary indications: anorexia associated with weight loss in AIDS patients and chemotherapy-induced nausea and vomiting. The drug is marketed under the brand name Marinol by AbbVie.

The global market for cannabinoid-based medications, including Dronabinol, is expanding, driven by increasing recognition of therapeutic cannabis use and shifting regulatory environments. However, Dronabinol's market share remains limited compared to newer formulations such as nabiximols and other medical cannabis products.

In 2022, the global pharmaceutical market for cannabinoids is valued approximately at $580 million, with a compound annual growth rate (CAGR) forecasted at about 12.3% from 2023 to 2030 ([1]).

How do regulatory frameworks impact Dronabinol's market?

Dronabinol holds FDA approval but faces regulatory variability globally:

• United States: Prescription-only status under FDA regulation. Considered a Schedule III controlled substance by the DEA.
• Canada: Legal for medical use under the Cannabis Act, with access through licensed providers.
• Europe: Limited approvals; some nations permit prescription for specific indications or in compounded form.
• Emerging Markets: Increasing acceptance but with complex regulatory pathways and licensing hurdles.

Strict regulation introduces high compliance costs and limits over-the-counter or broader market access.

What are the primary competitive factors affecting Dronabinol's market share?

• Alternative formulations: Sativex (nabiximols) and nabilone offer different delivery methods and formulations, creating competition.
• Medical cannabis legalization: Growing acceptance reduces reliance on synthetic options.
• Patent expirations: Dronabinol's patent has expired, leading to generic manufacturing, which lowers prices.
• Insurance coverage: Reimbursement policies influence prescribing patterns, with some insurers restricting coverage for synthetic THC drugs.

How does pricing influence market potential?

Dronabinol's wholesale price in the United States ranges from $120 to $160 per 1-mL capsule, with per-treatment costs fluctuating based on dosage and duration.

Generic competition has driven prices down by approximately 20%-30% between 2018 and 2022. The relative affordability impacts utilization rates, particularly in markets with limited insurance coverage or cost-sharing constraints.

What is the projected financial trajectory?

• Sales figures: Current annual revenues for Marinol hover around $300 million in the U.S.
• Market growth: Expected to grow modestly at a CAGR of 3%-5% through 2030 due to increased acceptance, but growth is constrained by competition from herbal cannabis and newer pharmaceuticals.
• Future prospects: Growth hinges on regulatory changes, expanded indications, and formulation innovations—such as novel delivery systems or combination drugs.

How might technological and policy developments alter future market dynamics?

• New formulations: Liposomal, transdermal, or inhalable Dronabinol alternatives could expand patient options.
• Regulatory liberalization: Countries easing restrictions could open new markets; cultural acceptance of medical cannabis broadens access.
• Reimbursement shifts: Insurance coverage expansion for cannabinoid-based therapies would improve affordability and access.
• Research advancements: Demonstration of efficacy for additional indications could increase prescription volumes.

Summary table: Key financial and market data

Metric	2022 Data	2030 Projection	Source
Market size (globally)	$580 million	~$1 billion	[1]
CAGR (2023-2030)	12.3%	12.3%	[1]
U.S. annual sales	~$300 million	Approx. similar, slow growth	Company reports
Patent status	Expired	N/A	Public records
Number of approved indications	2 (FDA approved)	Potential expansion (additional indications)	Regulatory filings

Key takeaways

1. The Dronabinol market experiences growth constrained by regulatory variability, market competition, and licensing hurdles.
2. Price reductions from generic production have stabilizing effects but limit revenue potential.
3. Market expansion depends on regulatory liberalization, new formulation development, and broader insurance coverage.
4. Competition from herbal cannabis products and alternative synthetic cannabinoids suppresses Dronabinol's market growth.
5. Advances in drug delivery and indications could provide new revenue streams while regulatory evolutions could unlock larger markets.

FAQs

Q1: How does Dronabinol's patent status affect its market?
Patent expiration allowed generic manufacturers to produce lower-cost versions, increasing competition and decreasing prices but limiting premium pricing for branded formulations.

Q2: Are there new formulations of Dronabinol in development?
No publicly announced new formulations are near commercialization, but research into alternative delivery systems continues.

Q3: What are the primary barriers to expanding Dronabinol's market?
Regulatory restrictions, competition from natural cannabis, and limited insurance reimbursement are key barriers.

Q4: How does legal cannabis legalization impact Dronabinol's market?
Legalization of recreational and medical cannabis reduces demand for synthetic options and introduces alternative products with similar therapeutic effects.

Q5: Which markets hold the most growth potential?
Emerging markets in Latin America, Asia, and certain European countries are expanding access, providing growth opportunities if regulatory barriers relax.

---

References

[1] Grand View Research. (2022). Cannabinoids Market Size, Share & Trends Analysis Report.